|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
21.26 USD |
+4.47% | -0.42% | -15.87% | |
Published on 06/14/2025 at 10:52
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Celldex Presents Data Demonstrating Profound Long Term Improvement In Angioedema In Barzolvolimab Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci 2025 |
10:52am |
RE |
|
Celldex Therapeutics, Inc. – Special Call |
Jun. 13 |
|
|
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 |
Jun. 12 |
CI |
|
Celldex Presents Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci Congress 2025 |
Jun. 12 |
RE |
|
Celldex Therapeutics Announces Election of Denice Torres to Its Board of Directors |
Jun. 06 |
CI |
|
UBS Adjusts Price Target on Celldex Therapeutics to $38 From $44, Maintains Buy Rating |
May. 09 |
MT |
|
Earnings Flash (CLDX) Celldex Therapeutics Reports Q1 Revenue $695K |
May. 08 |
MT |
|
Celldex Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 |
May. 08 |
CI |
|
Earnings Flash (CLDX) Celldex Therapeutics Reports Q1 Loss $0.81 Per Share, vs. FactSet Est of $-0.75 |
May. 08 |
MT |
|
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in This Difficult to Treat Disease |
May. 05 |
CI |
|
Canaccord Genuity Initiates Coverage on Celldex Therapeutics With Buy Rating, $64 Price Target |
Apr. 28 |
MT |
|
Morgan Stanley Initiates Celldex Therapeutics at Overweight With $46 Price Target |
Mar. 20 |
MT |
|
Celldex Therapeutics, Inc. Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life At Aaaai 2025 |
Mar. 01 |
CI |
|
Earnings Flash (CLDX) Celldex Therapeutics Reports Q4 Loss $-0.71 Per Share, vs. FactSet Est of $-0.74 |
Feb. 27 |
MT |
|
Earnings Flash (CLDX) Celldex Therapeutics Posts Q4 Revenue $1.2M, vs. FactSet Est of $1.0M |
Feb. 27 |
MT |
|
Celldex Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 |
Feb. 27 |
CI |
|
Celldex Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 |
Feb. 27 |
CI |
|
Celldex Therapeutics Doses First Patient in Study of Potential Inflammatory Disease Treatment |
Nov. 20 |
MT |
|
Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases |
Nov. 20 |
CI |
|
Earnings Flash (CLDX) CELLDEX THERAPEUTICS Reports Q3 Revenue $3.2M |
Nov. 06 |
MT |
|
Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q3 Loss $-0.64 |
Nov. 06 |
MT |
|
Celldex Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 |
Nov. 06 |
CI |
|
Celldex Therapeutics, Inc. – Special Call |
24-10-28 |
|
|
Celldex Therapeutics, Inc. Announces Positive Results from its Phase 2 Clinical Trial of Barzolvolimab |
24-10-26 |
CI |
|
Citigroup Initiates Celldex Therapeutics at Buy With $70 Price Target |
24-10-07 |
MT |
CLDX: Dynamic Chart
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Companyâs bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.
More about the company
Buy
Average target price
58.54USD
Spread / Average Target
+175.35%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
